The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
Immun Inflammation Dis
For people who wake up ravenous or need to get out the door quickly, that 60-90 minute wait can feel like an eternity
Between 2019 and 2023, the number of GLP-1 prescriptions increased by more than 400%, while spending increased by more than 500%
By far, citrate represents the largest byproduct of fatty acid oxidation in the brain
After each increase, blood levels peak over 24 to 72 hours, when nausea and fullness are most likely to return. These effects usually ease during the four-week hold